Drug development has always been a long and arduous process, taking years of research and costing millions of dollars. When some biotech companies started to use artificial intelligence as part of that process, it was seen as a tool that had the potential to revolutionize drug discovery. Ten years on, those companies are faced with a reality check. 

Globe business reporters Joe Castaldo, who covers AI, and Sean Silcoff, who reports on  technology and life sciences, are on the show to talk about the promise of AI in drug development, and why the bets on technology haven’t panned out. 

Questions? Comments? Ideas? Email us at [email protected]